Physician profile
Sidney K Smith
NPI 1922148162
$10,281.76
in general payments reported to CMS, 2019-2025
32 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $418 · 2021: $1,190 · 2022: $1,359 · 2023: $2,352 · 2024: $2,423 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,493 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,492.51 |
| Education | $112.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,998.50 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,035.23 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $672.81 | 2019-2025 | Spravato |
| Alkermes, INC. | $599.36 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $556.99 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $541.56 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $472.73 | 2020-2025 | Caplyta |
| Almatica Pharma LLC | $424.12 | 2021-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $420.14 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $384.66 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $383.81 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $334.20 | 2019-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $315.19 | 2019-2022 | |
| Tris Pharma INC | $309.37 | 2022-2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $259.14 | 2019-2025 | Ingrezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $228.18 | 2023-2025 | Xelstrym, Secuado |
| Eisai INC. | $227.04 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $193.46 | 2019-2022 | |
| Bioxcel Therapeutics, INC. | $179.08 | 2023 | Igalmi |
| Corium, LLC | $150.43 | 2022-2024 | Azstarys |
| Allergan, INC. | $136.60 | 2019-2020 | |
| Bausch Health US, LLC | $127.67 | 2019-2024 | Aplenzin, Wellbutrin |
| Acadia Pharmaceuticals INC | $94.16 | 2019-2022 | |
| Indivior INC. | $54.15 | 2021 | |
| Shire North American Group INC | $44.67 | 2019 | |
| Avanir Pharmaceuticals, INC. | $31.55 | 2021-2022 | |
| Brainsway USA INC | $24.37 | 2024 | Brainsway Deep Tms System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.08 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $15.40 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.73 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.